Valion Bio, Inc. Operating Lease Right-of-Use Assets
Valion Bio, Inc. (VBIO) had Operating Lease Right-of-Use Assets of $9.84 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-14
- 2026-06-30: Operating Lease, Right-of-Use Asset $9.84M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $10.09M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $0.00.
- 2024-03-31: Operating Lease, Right-of-Use Asset $304.00K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $9.84M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $10.09M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-14 |
| 2024-03-31 | $304.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $349.00K 10-K · filed 2025-03-21 |
| 2023-09-30 | $394.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $438.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $481.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $523.00K 10-K · filed 2024-03-25 |
| 2022-09-30 | $565.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $607.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $647.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $687.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |